Importance of Clinical Trials Participation

Only about 5% of women with a gynecologic cancer participate in the dozens of clinical trials in gynecologic cancers. The predominant hope for improving on the treatment options for women diagnosed with a gynecologic cancer is through the conduct of clinical trials.

The Foundation for Women’s Cancer actively works with the Gynecologic Oncology Group (GOG) to encourage women to participate in clinical trials. Clinical trials are a crucial step in finding new and improved ways to improve treatment for women diagnosed with a gynecologic cancer.

Three examples of the important advances in the care of women as a result of clinical trials include:

  • Chemotherapy added to radiation improve cure rate in locally advanced cervical cancer (GOG 120, 109)
  • Platinum based chemotherapy plus paclitaxel is superior to platinum based chemotherapy plus cyclophosphamide (GOG 111)
  • IP therapy improves survival in subsets of women with newly diagnosed advanced ovarian cancer (GOG 172)

The patients that participated in the phase III clinical trials that led to these discoveries were among the first to benefit from these scientific advancements.

Spotlight

Gynecologic oncologists discuss some of the most important research presented at the 2016 SGO Annual Meeting in San Diego. Ovarian cancer survivor and patient advocate Jocelyn Alfandre (pictured) was a featured speaker at the Annual Meeting.

Awareness

The Foundation is featured in the Sept. issues of Coping, Women and Family Circle magazines. Look out for our articles & ads!

Research

The Foundation is proud to offer various Research Grants and Awards. Click here for more information.

Education

FREE Gynecologic Cancer Survivors Courses throughout the country. For more information, click here.